A081105

Randomized, Double-blind, Placebo COntrolled Study of erlotinib or placebo in Patients with Completely Resected Epidermal Growth factor Receptor (EGFR) mutant Non-Small Cell Lung Cancer (NSCLC)
Contact phone
Nurse - Tracy 517-364-2835
Principal investigator
Gordon Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Lung